LicenseCompare

Monetary Authority of Singapore

Singapore MAS CMS corporate finance application pack

A practical evidence pack map for Singapore CMS applicants advising on corporate finance, including transaction scope, capital raising boundaries, representative RES 4 readiness, conflicts, due diligence, investor communications, and MAS Form 1 alignment.

Route focus

A corporate finance CMS application should prove whether the applicant advises issuers, boards, shareholders, acquirers, sellers, sponsors, fund raisers, or transaction participants, and whether any part of the model drifts into dealing, fund distribution, financial advisory services, or cross-border marketing.

Who this helps

  • - Singapore corporate finance advisers preparing MAS CMS licence materials
  • - Capital raising, M&A, restructuring, listing, and private markets advisory teams checking CMS route evidence
  • - Existing fund managers, broker-dealers, or advisory firms adding corporate finance mandates
  • - Compliance teams preparing RES 4, representative notification, transaction approval, conflicts, and deal-file controls

Licence scope

  • - Confirm whether the regulated activity is advising on corporate finance and whether the transaction workflow also includes dealing in capital markets products, arranging, fund marketing, financial advisory services, research, or introductions.
  • - Map mandates by issuer advisory, acquisition/disposal advice, restructuring, capital raising, private placement, public-market communication, takeover-style work, valuation, due diligence, and investor-facing activity.
  • - Identify client type, investor classification, overseas issuers/investors, success-fee arrangements, referral fees, syndicate roles, and group transaction desks before drafting the business plan.
  • - Separate corporate finance advice from securities dealing where the firm introduces investors, circulates offering material, arranges subscriptions, or receives transaction-linked compensation.

Pre-draft questions

  • - What corporate finance advice will the Singapore entity give, and to whom: issuer, board, shareholder, acquirer, seller, investor, fund sponsor, or group company?
  • - Will any person solicit investors, place securities, distribute fund interests, arrange subscriptions, prepare research, or introduce capital providers?
  • - Which representatives need RES 4 or other CMFAS evidence, and which people supervise conflicts, due diligence, valuation, client communications, and deal approvals?
  • - How will the firm document mandate acceptance, conflicts, inside information, wall-crossing, due diligence, valuation support, disclosure review, investor communications, and closing records?
  • - Does Form 1 align with engagement letters, pitch decks, transaction checklists, compensation terms, public-facing claims, representative files, and MAS FID/register expectations?

Evidence pack

Corporate finance route and transaction map

  • - Mandate taxonomy covering advisory, M&A, restructuring, capital raising, private placement, listing/public-market work, fund sponsor advice, investor introductions, and internal transaction support.
  • - Boundary memo separating advising on corporate finance from dealing in capital markets products, fund marketing, financial advisory services, research, and cross-border solicitation.
  • - Source packet covering MAS/GoBusiness CMS licence information, MAS Form 1, MAS representative notification/competency sources, IBF CMFAS RES 4 materials, and MAS FID checks.

People and representative evidence

  • - Representative matrix with RES 4 corporate finance route assumptions, role scope, deal experience, supervisor, fit and proper status, notification plan, and register-check owner.
  • - Transaction team map showing who originates, pitches, executes, reviews, signs off, controls conflicts, approves communications, and escalates material issues.
  • - Senior management evidence covering compliance, AML/CFT, risk, finance, operations, outsourcing, cyber, complaints, records, and information-barrier ownership.

Transaction controls and deal files

  • - Mandate acceptance, conflicts, independence, due diligence, valuation, disclosure, investor communication, financial promotion, anti-bribery, AML/CFT, sanctions, and recordkeeping controls.
  • - Capital raising file showing investor eligibility, communication approvals, subscription/placement workflow, referral or success-fee terms, and escalation where dealing analysis may be needed.
  • - Sample deal-file index with engagement letter, transaction committee notes, diligence requests, management meeting notes, verification evidence, communications approvals, closing checklist, and complaint/escalation records.

People and governance

  • - The corporate finance representative file should combine RES 4 or relevant CMFAS evidence with actual transaction role, supervision, authority, conflicts training, and notification status.
  • - Senior management should decide whether the firm only gives corporate finance advice or also arranges investors, markets securities, or deals in capital markets products.
  • - If group offices, overseas bankers, introducers, law firms, or placement agents are involved, document who controls the Singapore regulated activity and investor communications.
  • - Transaction approval, conflicts, wall-crossing, and records ownership should be named before submission, not invented after the first mandate.

Forms and submission

  • - Use MAS/GoBusiness CMS licence information and MAS Form 1 as the core submission map for advising on corporate finance.
  • - Prepare Form 1 around transaction types, client/investor roles, revenue model, representative plan, conflicts, due diligence, AML/CFT, outsourcing, technology, and financial resources.
  • - Use MAS SFA 04-N22, MAS CMS representative FAQ, AskGov competency answer, and IBF CMFAS materials to reconcile RES 4, notification, exemption, and CPD assumptions.
  • - After approval and representative notification, verify the firm and appointed representatives through MAS FID and relevant MAS representative records before taking client-facing mandates.

Timeline risks

  • - A corporate finance application becomes harder when the business model mixes advisory, investor introductions, private placement, fund marketing, and transaction compensation without a boundary memo.
  • - Weak deal-file controls, conflicts process, information barriers, communication approval, and due diligence evidence can create avoidable follow-up.
  • - Representative evidence can become stale if RES 4 is treated as a generic credential rather than tied to each person's actual deal role.
  • - Cross-border issuer/investor contacts, public offers, retail-facing communications, and fund-raising mandates need careful source-aligned review.

Questions to ask advisers

  • - Is the activity advising on corporate finance, dealing in capital markets products, fund marketing, financial advisory service, research, or several activities?
  • - Which representatives need RES 4 and which also need dealing or product-knowledge analysis?
  • - How does the firm prove conflicts control, due diligence, valuation support, investor communications review, and record retention?
  • - Which public-facing claims, pitch decks, and fee terms might make the application broader than the intended corporate finance route?

Common mistakes

  • - Calling a private placement or investor introduction purely corporate finance advice when dealing in capital markets products may also need analysis.
  • - Treating RES 4 as enough without representative notification, role-scope evidence, and supervision.
  • - Submitting generic compliance policies that do not explain mandate acceptance, conflicts, due diligence, valuation, and communications review.
  • - Ignoring cross-border marketing, referral-fee, success-fee, and public-offer facts until after Form 1 is drafted.

Disclaimer

Information on LicenseCompare is for general educational purposes only and does not constitute legal, regulatory, financial, tax, investment, or professional advice. Licensing requirements depend on facts and change over time. Always consult official regulator materials and qualified professional advisers.